Published in J Thorac Oncol on December 01, 2010
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer. J Biomed Biotechnol (2012) 0.76
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer (2006) 2.52
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis (2004) 1.92
Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res (2009) 1.91
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol (2005) 1.64
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer (2007) 1.48
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res (2004) 1.45